Готові списки джерел за темами / Digestive cancers

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Добірка наукової літератури з теми "Digestive cancers"

Автор: Grafiati
Опубліковано: 11 січня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Digestive cancers".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Digestive cancers"

1

Zhang, Tao, Bofang Wang, Baohong Gu, Fei Su, Lin Xiang, Le Liu, Xuemei Li, Xueyan Wang, Lei Gao, and Hao Chen. "Genetic and Molecular Characterization Revealed the Prognosis Efficiency of Histone Acetylation in Pan-Digestive Cancers." Journal of Oncology 2022 (April 5, 2022): 1–21. http://dx.doi.org/10.1155/2022/3938652.

Повний текст джерела
Анотація:
The imbalance between acetylation and deacetylation of histone proteins, important for epigenetic modifications, is closely associated with various diseases, including cancer. However, knowledge regarding the modification of histones across the different types of digestive cancers is still lacking. The purpose of this research was to analyze the role of histone acetylation and deacetylation in pan-digestive cancers. We systematically characterized the molecular alterations and clinical relevance of 13 histone acetyltransferase (HAT) and 18 histone deacetylase (HDAC) genes in five types of digestive cancers, including esophageal carcinoma, gastric cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer. Recurrent mutations and copy number variation (CNV) were extensively found in acetylation-associated genes across pan-digestive cancers. HDAC9 and KAT6A showed widespread copy number amplification across five pan-digestive cancers, while ESCO2, EP300, and HDAC10 had prevalent copy number deletions. Accordingly, we found that HAT and HDAC genes correlated with multiple cancer hallmark-related pathways, especially the histone modification-related pathway, PRC2 complex pathway. Furthermore, the expression pattern of HAT and HDAC genes stratified patients with clinical benefit in hepatocellular carcinoma and pancreatic cancer. These results indicated that acetylation acts as a key molecular regulation of pan-digestive tumor progression.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Yang, Ting-Fang, Xin-Rui Li, and Mo-Wei Kong. "Molecular mechanisms underlying roles of long non-coding RNA small nucleolar RNA host gene 16 in digestive system cancers." World Journal of Gastrointestinal Oncology 16, no. 11 (November 15, 2024): 4300–4308. http://dx.doi.org/10.4251/wjgo.v16.i11.4300.

Повний текст джерела
Анотація:
This editorial reviews the molecular mechanisms underlying the roles of the long non-coding RNA (lncRNA) small nucleolar RNA host gene 16 (SNHG16 ) in digestive system cancers based on two recent studies on lncRNAs in digestive system tumors. The first study, by Zhao et al , explored how hBD-1 affects colon cancer, via the lncRNA TCONS_00014506 , by inhibiting mTOR and promoting autophagy. The second one, by Li et al , identified the lncRNA prion protein testis specific (PRNT ) as a factor in oxaliplatin resistance by sponging ZNF184 to regulate HIPK2 and influence colorectal cancer progression and chemoresistance, suggesting PRNT as a potential therapeutic target for colorectal cancer. Both of these two articles discuss the mechanisms by which lncRNAs contribute to the development and progression of digestive system cancers. As a recent research hotspot, SNHG16 is a typical lncRNA that has been extensively studied for its association with digestive system cancers. The prevailing hypothesis is that SNHG16 participates in the development and progression of digestive system tumors by acting as a competing endogenous RNA, interacting with other proteins, regulating various genes, and affecting downstream target molecules. This review systematically examines the recently reported biological functions, related molecular mechanisms, and potential clinical significance of SNHG16 in various digestive system cancers, and explores the relationship between SNHG16 and digestive system cancers. The findings suggest that SNHG16 may serve as a potential biomarker and therapeutic target for human digestive system cancers.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Stokłosa, Paulina, Anna Borgström, Sven Kappel, and Christine Peinelt. "TRP Channels in Digestive Tract Cancers." International Journal of Molecular Sciences 21, no. 5 (March 9, 2020): 1877. http://dx.doi.org/10.3390/ijms21051877.

Повний текст джерела
Анотація:
Cancers of the digestive tract are among the most prevalent types of cancer. These types of cancers are often diagnosed at a late stage, which results in a poor prognosis. Currently, many biomedical studies focus on the role of ion channels, in particular transient receptor potential (TRP) channels, in cancer pathophysiology. TRP channels show mostly non-selective permeability to monovalent and divalent cations. TRP channels are often dysregulated in digestive tract cancers, which can result in alterations of cancer hallmark functions, such as enhanced proliferation, migration, invasion and the inability to induce apoptosis. Therefore, TRP channels could serve as potential diagnostic biomarkers. Moreover, TRP channels are mostly expressed on the cell surface and ion channel targeting drugs do not need to enter the cell, making them attractive candidate drug targets. In this review, we summarize the current knowledge about TRP channels in connection to digestive tract cancers (oral cancer, esophageal cancer, liver cancer, pancreatic cancer, gastric cancer and colorectal cancer) and give an outlook on the potential of TRP channels as cancer biomarkers or therapeutic targets.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Zhang, Nan, Yueying Wang, Gary Tse, Guangping Li, Shouling Wu, and Tong Liu. "Association of Visit-to-Visit Variability in Fasting Plasma Glucose with Digestive Cancer Risk." Oxidative Medicine and Cellular Longevity 2022 (July 13, 2022): 1–12. http://dx.doi.org/10.1155/2022/4530894.

Повний текст джерела
Анотація:
Background and Aims. The aim of this study is to investigate the association between visit-to-visit variability in fasting plasma glucose (FPG) and the risk of digestive cancers among individuals with and without diabetes. Methods. Using data from Kailuan cohort, a prospective population-based study, individuals who had at least two measurements of FPG between 2006 and 2012 without prior cancer were included in this study. Four indexes of variability were used, including standard deviation (SD), coefficient of variation (CV), variability independent of the mean (VIM), and average successive variability (ARV). Cox regression was used to evaluate the relationship between the quartiles of FPG variability and digestive cancers. Results. A total of 98,161 individuals were studied. Over a mean follow-up of 9.32 ± 0.81 years, 1103 individuals developed incident digestive cancer (1.21 per 1000 person-years). Compared to the individuals in the lowest quartile, those in the highest quartile of FPG variability by SD had 38.7% higher risk of developing overall digestive cancers after adjusting for the significant confounders (hazard ratio, 1.387; 95% confidence interval, 1.160-1.659; P = 0.0003 ). Higher FPG variability was associated with significantly higher risks of colorectal cancer (fully adjusted HR 1.432, 95% CI [1.073-1.912], P = 0.015 ) and pancreatic cancer (fully adjusted HR 2.105, 95% CI [1.024-4.329], P = 0.043 ), but not liver cancer (fully adjusted HR 1.427, 95% CI [0.973-2.092], P = 0.069 ) or esophageal and gastric cancer (fully adjusted HR 1.139, 95% CI [0.776-1.670], P = 0.506 ). Subgroup analyses showed that individuals who were younger (<65 years), male, and those without diabetes experienced a predominantly higher risk of developing digestive cancers. Similar results were observed when using CV, VIM, and ARV. Conclusions. FPG variability was significantly associated with increasing risk of digestive cancers, especially for pancreatic and colorectal cancer. Our study suggested a potential role of FPG variability in risk stratification of digestive cancers. Approaches that reduce FPG variability may lower the risks of incident digestive cancers among the general population. This trial is registered with ChiCTR-TNRC-11001489.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Ishikawa, Marin, Kohei Nakamura, Ryutaro Kawano, Hideyuki Hayashi, Tatsuru Ikeda, Makoto Saito, Yo Niida, et al. "Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan." Cancers 16, no. 8 (April 15, 2024): 1504. http://dx.doi.org/10.3390/cancers16081504.

Повний текст джерела
Анотація:
The usefulness of comprehensive genomic profiling (CGP) in the Japanese healthcare insurance system remains underexplored. Therefore, this large-scale study aimed to determine the usefulness of CGP in diagnosing digestive cancers. Patients with various cancer types recruited between March 2020 and October 2022 underwent the FoundationOne® CDx assay at the Keio PleSSision Group (19 hospitals in Japan). A scoring system was developed to identify potentially actionable genomic alterations of biological significance and actionable genomic alterations. The detection rates for potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to companion diagnosis (CDx), as well as the signaling pathways associated with these alterations in each digestive cancer, were analyzed. Among the 1587 patients, 547 had digestive cancer. The detection rates of potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to CDx were 99.5%, 62.5%, and 11.5%, respectively. APC, KRAS, and CDKN2A alterations were frequently observed in colorectal, pancreatic, and biliary cancers, respectively. Most digestive cancers, except esophageal cancer, were adenocarcinomas. Thus, the classification flowchart for digestive adenocarcinomas proposed in this study may facilitate precise diagnosis. CGP has clinical and diagnostic utility in digestive cancers.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Reitano, Elisa, Nicola de’Angelis, Paschalis Gavriilidis, Federica Gaiani, Riccardo Memeo, Riccardo Inchingolo, Giorgio Bianchi, Gian Luigi de’Angelis, and Maria Clotilde Carra. "Oral Bacterial Microbiota in Digestive Cancer Patients: A Systematic Review." Microorganisms 9, no. 12 (December 14, 2021): 2585. http://dx.doi.org/10.3390/microorganisms9122585.

Повний текст джерела
Анотація:
The relation between the gut microbiota and human health is increasingly recognized. Recently, some evidence suggested that dysbiosis of the oral microbiota may be involved in the development of digestive cancers. A systematic review was conducted according to the PRISMA guidelines to investigate the association between the oral microbiota and digestive cancers. Several databases including Medline, Scopus, and Embase were searched by three independent reviewers, without date restriction. Over a total of 1654 records initially identified, 28 studies (2 prospective cohort studies and 26 case-controls) were selected. They investigated oral microbiota composition in patients with esophageal squamous cell carcinoma (n = 5), gastric cancer (n = 5), colorectal cancer (n = 9), liver carcinoma (n = 2), and pancreatic cancer (n = 7). In most of the studies, oral microbiota composition was found to be different between digestive cancer patients and controls. Particularly, oral microbiota dysbiosis and specific bacteria, such as Fusobacterium nucleatum and Porphyromonas gingivalis, appeared to be associated with colorectal cancers. Current evidence suggests that differences exist in oral microbiota composition between patients with and without digestive cancers. Further studies are required to investigate and validate oral–gut microbial transmission patterns and their role in digestive cancer carcinogenesis.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Turati, Federica, Marta Rossi, Claudio Pelucchi, Fabio Levi, and Carlo La Vecchia. "Fruit and vegetables and cancer risk: a review of southern European studies." British Journal of Nutrition 113, S2 (April 2015): S102—S110. http://dx.doi.org/10.1017/s0007114515000148.

Повний текст джерела
Анотація:
High intakes of fruit and vegetables may reduce the risk of cancer at several sites. Evidence has been derived mainly from case–control studies. We reviewed the relationship between consumption of vegetables and fruit and the risk of several common cancers in a network of Italian and Swiss case–control studies including over 10 000 cases of fourteen different cancers and about 17 000 controls. Data were suggestive of a protective role of vegetable intake on the risk of several common epithelial cancers. OR for the highest compared with the lowest levels of consumption ranged from 0·2 (larynx, oral cavity and pharynx) to 0·9 (prostate). Inverse associations were found for both raw and cooked vegetables, although for upper digestive tract cancers the former were somewhat stronger. Similar inverse associations were found for cruciferous vegetables. Frequent consumption of allium vegetables was also associated with reduced risk of several cancers. Fruit was a favourable correlate of the risk of several cancers, particularly of the upper digestive tract, with associations generally weaker than those reported for vegetables. A reduced risk of cancers of the digestive tract and larynx was found for high consumption of citrus fruit. Suggestive protections against several forms of cancer, mainly digestive tract cancers, were found for high consumption of apples and tomatoes. High intakes of fibres, flavonoids and proanthocyanidins were inversely related to various forms of cancer. In conclusion, data from our series of case–control studies suggested a favourable role of high intakes of fruit and vegetables in the risk of many common cancers, particularly of the digestive tract. This adds evidence to the indication that aspects of the Mediterranean diet may have a favourable impact not only on CVD, but also on several common (epithelial) cancers, particularly of the digestive tract.
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Capparelli, Rosanna, Paola Cuomo, Antonio Gentile, and Domenico Iannelli. "Microbiota–Liver Diseases Interactions." International Journal of Molecular Sciences 24, no. 4 (February 15, 2023): 3883. http://dx.doi.org/10.3390/ijms24043883.

Повний текст джерела
Анотація:
Gut microbiota regulates essential processes of host metabolism and physiology: synthesis of vitamins, digestion of foods non-digestible by the host (such as fibers), and—most important—protects the digestive tract from pathogens. In this study, we focus on the CRISPR/Cas9 technology, which is extensively used to correct multiple diseases, including liver diseases. Then, we discuss the non-alcoholic fatty liver disease (NAFLD), affecting more than 25% of the global population; colorectal cancer (CRC) is second in mortality. We give space to rarely discussed topics, such as pathobionts and multiple mutations. Pathobionts help to understand the origin and complexity of the microbiota. Since several types of cancers have as target the gut, it is vital extending the research of multiple mutations to the type of cancers affecting the gut–liver axis.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Xiong, Zuming, Yongjun Yang, Wenxin Li, Yirong Lin, Wei Huang, and Sen Zhang. "Exploring Key Biomarkers and Common Pathogenesis of Seven Digestive System Cancers and Their Correlation with COVID-19." Current Issues in Molecular Biology 45, no. 7 (June 30, 2023): 5515–33. http://dx.doi.org/10.3390/cimb45070349.

Повний текст джерела
Анотація:
Digestive system cancer and COVID-19 significantly affect the digestive system, but the mechanism of interaction between COVID-19 and the digestive system cancers has not been fully elucidated. We downloaded the gene expression of COVID-19 and seven digestive system cancers (oral, esophageal, gastric, colorectal, hepatocellular, bile duct, pancreatic) from GEO and identified hub differentially expressed genes. Multiple verifications, diagnostic efficacy, prognostic analysis, functional enrichment and related transcription factors of hub genes were explored. We identified 23 common DEGs for subsequent analysis. CytoHubba identified nine hub genes (CCNA2, CCNB1, CDKN3, ECT2, KIF14, KIF20A, KIF4A, NEK2, TTK). TCGA and GEO data validated the expression and excellent diagnostic and prognostic ability of hub genes. Functional analysis revealed that the processes of cell division and the cell cycle were essential in COVID-19 and digestive system cancers. Furthermore, six related transcription factors (E2F1, E2F3, E2F4, MYC, TP53, YBX1) were involved in hub gene regulation. Via in vitro experiments, CCNA2, CCNB1, and MYC expression was verified in 25 colorectal cancer tissue pairs. Our study revealed the key biomarks and common pathogenesis of digestive system cancers and COVID-19. These may provide new ideas for further mechanistic research.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Adianto Nugroho, Fransicus Arifin, Perwira Widianto, Agung Ari Wibowo, A. Yuda Handaya, Iwan Kristian, M Iqbal Rivai, et al. "Digestive Surgery Services in COVID-19 Pandemic Period: Indonesian Society of Digestive Surgeons Position Statement." Journal Of The Indonesian Medical Association 70, no. 6 (July 16, 2020): 132–41. http://dx.doi.org/10.47830/jinma-vol.70.6-2020-239.

Повний текст джерела
Анотація:
Digestive surgery service including surgical management of gastrointestinal disease and digestive cancers are experiencing the impact of COVID-19 pandemic. Therefore it is necessary to formulate recommendation for digestives surgery service, as guidelines to engage in case-by-case assessment of particular patients with digestive diseases. We are aware that the knowledge and science of COVID-19 are still evolving, with new progression every day. This recommendation reflect actual condition and are subject for future adjustment in the future.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Digestive cancers"

1

Macaire, Pauline. "Modélisation par une approche de population de l’effet des facteurs de croissance granulocytaire lors de neutropénies chimio-induites." Thesis, Bourgogne Franche-Comté, 2020. http://www.theses.fr/2020UBFCJ001.

Повний текст джерела
Анотація:
Les travaux de cette thèse s'appuient sur les résultats d'une étude de cohorte ayant pour objectif principal de définir le schéma optimal d'administration prophylactique des facteurs de croissance granulocytaire (G-CSF) dans le cadre d’un traitement par FOLFIRINOX. Pour ce faire, un modèle pharmacocinétique/pharmacodynamique (PK/PD) a été construit pour décrire l'évolution des polynucléaires neutrophiles (PNN) en fonction du temps dans notre population en tenant compte de l'effet neutropéniant des trois chimiothérapies administrées mais également de l'effet stimulant des G-CSF exogènes sur la prolifération et la maturation des neutrophiles. Sur la base des estimations des paramètres du modèle obtenus, des simulations ont été réalisées afin de déterminer l'incidence et la durée des neutropénies pour chaque schéma prophylactique de G-CSF selon le début, la durée mais également la nature du traitement (formulation pegylée ou non). Pour réaliser ces simulations, la valeur initiale en PNN avant le début du cycle de chimiothérapie a été considérée; en cas de concentration initiale élevée (> 6,5 G/L), l'utilisation d'un traitement prophylactique ne semble pas nécessaire du fait d'un risque de neutropénie limitée. Par ailleurs, pour les patients dont la concentration initiale en PNN se situe en dessous de 6,5 G/L, au vu de nos résultats, une administration unique de peg-G-CSF 24 heures après la fin de la perfusion de 5-FU de 46 heures semble le schéma prophylactique le plus approprié pour réduire l'incidence et la durée des neutropénies induites par le FOLFIRINOX. Néanmoins, contrairement aux idées reçues, l'augmentation de la durée d'injections quotidiennes de G-CSF ou une administration tardive des facteurs de croissance granulocytaire n'est pas forcément profitable pour les patients du fait de l'augmentation de l'incidence des neutropénies sévères par rapport à la non-administration de traitement prophylactique
The work of this thesis is based on results of a cohort study whose main objective was to define the optimal schedule of prophylactic administration of granulocyte growth factors (G-CSF) in the context of FOLFIRINOX treatment. For this purpose, a pharmacokinetic/pharmacodynamic (PK/PD) model was built to describe the absolute neutrophil counts (ANC) time course in our population, including the three chemotherapies neutropenic effect, but also the stimulating effect of exogenous G-CSF on the proliferation and maturation of neutrophils. Based on the estimates of the model parameters, simulations were performed to determine the incidence and duration of neutropenia for each prophylactic G-CSF schedule depending on the begining, the duration but also the nature of the treatment (pegylated formulation or not). The pre-therapeutic ANC value was considered; in case of high initial ANC (> 6.5 G/L), the use of prophylactic treatment does not seems necessary due to the limited risk of neutropenia. Furthermore, for patients whose initial ANC is below 6.5 G/L, based on our results, a single administration of peg-G-CSF 24 hours after the end of the 46 hours 5-FU infusion seems to be the most appropriate prophylactic schedule to reduce the incidence and the duration of FOLFIRINOX-induced neutropenia. However, contrary to popular belief, increasing the number of daily G-CSF injections or late administration of G-CSF is not necessarily beneficial for patients due to the increased incidence of severe neutropenia compared to the absence of treatment
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Väkeväinen, Satu. "Local acetaldehyde production as a pathogenetic factor for upper digestive tract cancers in humans." Helsinki : University of Helsinki, 2002. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/vakevainen/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Vila, Casadesús Maria. "Design of bioinformatic tools for integrative analysis of microRNA-mRNA interactome applied to digestive cancers." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/663087.

Повний текст джерела
Анотація:
En esta tesis se han desarrollado e implementado distintas herramientas bioinformáticas que permiten el estudio de las interacciones miRNA-mRNA en contextos celulares específicos. oncretamente se ha creado un paquete de R (miRComb) que calcula las interacciones miRNA-mRNA partiendo de expresión de miRNAs y mRNAs, y predicciones bloinformáticas de bases de datos preexistentes. Las interacciones miRNA-mRNA finales son aquellas que muestran una correlación negativa y han estado predichas por al meno una base de datos. Como valor añadido, el paquete miRComb realiza un resumen en pdf con los resultados básicos del análisis (número de interacciones, número de mRNAs target por miRNA, análisis funcional, etc.), que permite comparar los datos de distintos estudios. Hemos aplicado esta metodología en el contexto de cánceres digestivos. En un primer estudio hemos utilizado datos públicos de 5 cánceres digestivos (colon, recto, esófago, stómago e hígado) y hemos determinado las interacciones miRNA-mRNA comunes entre ellos y específicas de cada uno. En un segundo estudio, hemos utilizado la misma metodología para analizar datos de IRNA-mRNA en biopsias de pacientes del Hospital Clínic de Barcelona con cáncer de páncreas. En este estudio hemos descrito interacciones miRNA-mRNA en el contexto de cáncer pancreático y hemos podido validar dos de ellas a nivel experimental. En resumen, podemos concluir que el paquete miRComb es una herramienta útil para el estudio del interactoma de miRNA-mRNA, y que ha servido para establecer hipótesis biológicas que luego se han podido comprobar en el laboratorio.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Perrichet-Pechinez, Anaïs. "Ciblage de l'IL-1beta pour améliorer l'efficacité de la chimio-immunothérapie dans le cancer." Electronic Thesis or Diss., Bourgogne Franche-Comté, 2024. http://www.theses.fr/2024UBFCI014.

Повний текст джерела
Анотація:
L'IL-1b est connue pour avoir un rôle ambivalent dans le microenvironnement tumoral. Le cancer du poumon et le cancer colorectal figurent parmi les cancers les plus meurtriers, et l'incidence de l'adénocarcinome canalaire pancréatique a considérablement augmenté au cours des 30 dernières années. Ce projet vise à étudier le rôle de l'IL-1b dans les cancers du poumon, du côlon et du pancréas en condition de traitement par chimio-immunothérapie et démontrer comment cette interleukine agit dans le microenvironnement tumoral afin d’identifier des pistes d’amélioration thérapeutique.Dans le cancer du poumon non à petites cellules, l'IL-1b a un rôle antitumoral en présence de chimio-immunothérapie, en participant au recrutement des cellules T CD8+ via la production de CXCL10 par les cellules cancéreuses. En revanche, dans les cancers digestifs tels que ceux du pancréas et du côlon, l'IL-1b joue un rôle pro-tumoral en favorisant l’immunosuppression dans le microenvironnement tumoral, augmentant ainsi la résistance aux traitements.Ainsi, la compréhension du rôle et des interactions spécifiques de l'IL-1b dans différents microenvironnements tumoraux pourrait offrir des perspectives pour développer des stratégies thérapeutiques ciblées et plus efficaces
IL-1β is known to have an ambivalent role in the tumor microenvironment. Lung cancer and colorectal cancer are among the deadliest cancers, and the incidence of pancreatic ductal adenocarcinoma has significantly increased over the past 30 years. This project aim to study the role of IL-1β in lung, colon, and pancreatic cancers in a context of chemo-immunotherapy, and investigate how this interleukin functions within the tumor microenvironment, to identify potential therapeutic improvements.In non-small cell lung cancer, IL-1β exhibits an antitumor role in the presence of chemoimmunotherapy by contributing to the recruitment of CD8+ T cells through the production of CXCL10 by cancer cells. Conversely, in digestive cancers such as pancreatic and colon cancers, IL-1β plays a pro-tumoral role by promoting immunosuppression within the tumor microenvironment, thereby increasing resistance to treatments.Thus, understanding the specific roles and interactions of IL-1β in different tumor microenvironments could offer insights for developing more targeted and efficient therapeutic strategies
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Cui, Yan. "Polymorphism of xeroderma pigmentosum group G and dietary flavonoid intake on the risk of lung and upper aero-digestive tract cancers." Diss., Restricted to subscribing institutions, 2005. http://proquest.umi.com/pqdweb?did=954047411&sid=1&Fmt=2&clientId=1564&RQT=309&VName=PQD.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Gupta, Bhawna. "Life-course approach to behavioural risk factors and quality of life for cancers of the upper aero-digestive tract in an Indian population: a case-control study." Thesis, Griffith University, 2018. http://hdl.handle.net/10072/371971.

Повний текст джерела
Анотація:
The incidence and mortality rates of cancers of upper aero-digestive tract (UADT) remain significantly high in India. These cancers, which occur more commonly in later adulthood, are influenced by social and lifestyle behaviours carried out during childhood, adolescence and early adult life. Thus, life-course epidemiology attempts to assess varying health effects of various risk factors, according to timing, duration and frequency of exposure, which may give important clues to the causes of cancer. These cancers have serious impacts on quality of life (QoL) as they involve anatomical structures essential for mastication, speaking, cosmetic appearance and psychological wellbeing. Moreover, these cancers frequently present late and progress rapidly. Therefore, there is a need to develop a model for cost-effective screening and detection of individuals at high-risk of these cancers in the near future as well as early detection of cancer cases. Thereby, a study was designed with the following hypotheses:  Early age at initiation, frequency and duration of use of tobacco in its all forms, exposure to second hand tobacco smoke (SHS) at home and drinking alcohol has a linear dose-response relationship with the incidence of UADT cancers.  There is an association between tobacco, alcohol drinking, diet, oral hygiene and anthropometry measures with incidence of oral cancers.  Cancer site, staging, gender and age at diagnosis have an impact on QoL.  A risk-factor based screening model for UADT cancers has strong predictive ability to detect high-risk individuals. A bi-centre hospital-based frequency matched case-control study was conducted in Pune, Maharashtra State, India, from June 2014 and May 2015. Cases were histopathologically confirmed new cases of squamous cell carcinoma of UADT. Controls were patients diagnosed with a disease other than UADT or any other cancer, selected from the same hospital during the same period as the cases were recruited. Data were collected by medical-record abstraction, face-face interviews and by visual inspection of the oral cavity. A closed-ended questionnaire with a life-course perspective was used to collect patient‟s self-reported information on sociodemographics, lifestyle habits (chewing and smoking tobacco, drinking alcohol, SHS, oral hygiene) and QoL. The interviewer recorded anthropometry measures and number of missing teeth. Unconditional logistic regression was used to estimate the odds ratios (ORs) and their corresponding 95% confidence intervals (CIs). A reciever-operater characterstic curve was plotted against sensitivity and false-positive rate to produce a cut off point for the presence of UADT cancers. Examination of all QoL domains was done using oneway analysis of variance and the Bonferroni adjustments for post-hoc comparisons. Data were analysed by the Statistical Package for Social Sciences version 22. A total of 480 patients participated in the study. Chewing tobacco emerged as the strongest predictor for UADT cancers (OR=7.61; 95% CI 4.65-12.45) followed by smoking and drinking alcohol. Exposure to SHS during childhood (<16 years) rather than after ≥16 years increased the risk significantly (OR=4.05; 95% CI 2.06-7.95). There is a linear dose-response relationship between duration, frequency and early age at initiation for lifestyle risk factors (chewing and smoking tobacco; drinking alcohol) with incidence of UADT cancers in adulthood. Combined effects of tobacco and alcohol consumption habits elevated the risk (OR=12.05; 95% CI 4.61-31.49) in comparison to never users of these habits. Furthermore, the combination of these three lifestyle risk factors accounted for 86.82% of population attributable risk. Overall, the most affected QoL domains were anxiety and mood both among cases and controls. Oropharynx and hypopharynx cancer cases had the worst mean scores across all QoL domains. Stage IV cancer patients showed the worst QoL. Amongst UADT cancers in Pune, cancer of the oral cavity was the most common. Chewing tobacco showed higher odds (OR=8.51; 95% CI 4.90-14.77) for oral cancer risk as compared to UADT cancers. Poor oral hygiene emerged as significant predictor for oral cancer risk (OR=6.98; 95% CI 3.72-13.05). A screening model was derived for detection of individuals at high-risk for UADT cancers. This model has high sensitivity (93.5%), specificity (71.1%), false positive rate (28.8%), false negative rate (6.4%), positive predictive value (74.8%) and negative predictive value (96.6%). Our research recognises the framework of life-course influences of early exposure to behavioural risk-factors as independent and combined predictors of UADT cancers. The significantly compromised QoL in UADT cancer needs to be incorporated as an outcome measure in an individualized approach to therapeutic and palliative care planning of these cases to enable a better quality of survival. If validated in other studies, our proposed screening model can be applicable to many other high-risk UADT cancer populations with behavioural risk factors similar to our study population.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Dentistry and Oral Health and Menzies Health Institute Queensland
Griffith Health
Full Text
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Chen, Jun 1969. "The association between dietary intake and the risk of cancers of the upper aero-digestive tract : a case-control study in Brazil." Thesis, McGill University, 2002. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=29422.

Повний текст джерела
Анотація:
Cancers of the upper aero-digestive tract (UADT) rank as the fifth most common neoplastic disease worldwide. Two identified risk contributors are consumption of tobacco and alcohol. Among all other potential etiological factors, diet has long been recognized to play an important role in the development of cancers of the UADT. Data from a multi-centre, hospital-based case-control study conducted in Brazil were used to assess the association of dietary intake with the risk of cancers of the UADT. Dietary assessment was made in terms of estimated intake of nutrients, specific foods and food groups. After adjusting for the effects of alcohol and tobacco consumption as well as empirical confounders, protective effects against cancer of the mouth (Odds Ratio (OR) = 0.61, 95% confidence interval (95% CI): 0.4--1.0) and the pharynx (OR = 0.51, 95%CI: 0.3--0.9) were found for consumption of citric fruits. (Abstract shortened by UMI.)
Стилі APA, Harvard, Vancouver, ISO та ін.
8

He, Hua, and 何華. "Anti-tumor mechanisms of cyclooxygenase inhibitors and a c-Jun-N-terminal kinase inhibitor in gastrointestinal cancers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B30075245.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Collard, Olivier Conroy Philippe. "Chirurgie des métastases hépatiques dans les cancers colo-rectaux étude rétrospective de 84 patients opérés au Centre Alexis Vautrin et en chirurgie digestive générale, CHU de Nancy de 1985 à 2000 /." [S.l.] : [s.n.], 2002. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2002_COLLARD_OLIVIER.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Moura, Kelly Cristina Rodrigues de [UNESP]. "Análise da frequencia do polimorfismo rs12979860 C/T no gene IL28B em pacientes acometidos por câncer gástrico." Universidade Estadual Paulista (UNESP), 2015. http://hdl.handle.net/11449/126466.

Повний текст джерела
Анотація:
Made available in DSpace on 2015-08-20T17:09:51Z (GMT). No. of bitstreams: 0 Previous issue date: 2015-02-26. Added 1 bitstream(s) on 2015-08-20T17:26:18Z : No. of bitstreams: 1 000839769.pdf: 1095151 bytes, checksum: 5c5372db38bb52b66a5da5b0b13785b5 (MD5)
O câncer gástrico é um dos tipos de câncer mais comum e está associado com uma alta frequência de mortalidade. Embora nas últimas décadas tenha ocorrido um decréscimo na incidência mundial, o prognóstico desta patologia permanece ruim, principalmente quando o diagnóstico é feito em estágios avançados. A etiologia é complexa e multifatorial, onde a combinação de fatores genéticos e ambientais parecem estar envolvidos na carcinogênese e progressão da doença. Desta forma, o objetivo deste estudo foi determinar a frequência do polimorfismo rs12979860 C/T no gene IL28B em amostras de carcinoma gástrico provenientes de dois estados brasileiros, São Paulo e Ceará, associando às características clínicas e epidemiológicas desses pacientes. Os resultados demonstraram que 29,7% dos pacientes apresentam o genótipo CC, enquanto a frequência dos indivíduos heterozigotos e (CT) e homozigotos (TT) foram 56,3% e 9%, respectivamente. Em comparação com dados descritos na literatura e do dBSNP de populações usadas como controle, a frequência do alelo T foi mais alta nos pacientes acometidos por câncer gástrico (tumor difuso: 45,5%, tumor intestinal: 39%, literatura: 11 a 35 e dBSNP: 36%). Ainda neste contexto, encontramos uma significante menor frequência do genótipo CC entre os pacientes acometidos por tumores difusos (22,7%), quando comparados aos indivíduos saudáveis (44 a 51%). Nos casos provenientes da população cearense o alelo C foi significativamente mais elevado no tipo intestinal (67%) quando comparado ao tipo difuso (50%), ressaltando a maior frequência do alelo T nos casos difusos. Analisando-se a frequência do polimorfismo rs12979860 C/T e a genotipagem de Helicobacter pylori foi observada uma forte associação entre o genótipo e a infecção pela bactéria CagA+, onde pacientes portadores da cepa mais patogênica (CagA+) apresentaram frequência maior do genótipo menos protetor (TT), principalmente no...
Gastric cancer is one of the most common types of cancer and is associated with a high mortality rate. Although in recent decades there has been a decrease in the global incidence, prognosis of this condition remains poor, especially when the diagnosis is made in advanced stages. The etiology is complex and multifactorial, where the combination of genetic and environmental factors appear to be involved in carcinogenesis and progression of the disease. Thus, the aim of this study was to determine the frequency of the polymorphism rs12979860 C / T in the IL28B gene in gastric carcinoma samples from two Brazilian states, São Paulo and Ceará, associating the clinical and epidemiological characteristics of these patients. The results showed that 29.7% of patients present with the CC genotype, while the frequency of heterozygotes and (TC) and homozygous (TT) were 56.3% and 9%, respectively. Compared to data reported in the literature and used as control populations of dbSNP, the frequency of the T allele was higher in patients affected by gastric cancer (diffuse tumor: 45.5%, intestinal tumor: 39%, literature: 11-35 and dbSNP: 36%). Also in this context, we found a significant lower frequency of the CC genotype among patients affected by diffuse tumors (22.7%) when compared to healthy subjects (44-51%). In cases from Ceará population the C allele was significantly higher in the intestinal type (67%) compared to the diffuse type (50%), emphasizing the greater frequency of the T allele in diffuse cases. Analyzing the frequency of polymorphism rs12979860 C / T and genotyping of Helicobacter pylori was observed a strong association between genotype and infection with CagA + bacteria, where patients with the most pathogenic strain (CagA +) had a frequency higher than genotype less protective (TT), particularly in diffuse histotype (p = 0.001). In addition, this same allele was significantly associated with the occurrence of metastases in ...
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Digestive cancers"

1

P, Griffin-Sobel Joyce, and Oncology Nursing Society, eds. Gastrointestinal cancers. Pittsburgh: Oncology Nursing Society, 2007.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Takahashi, Toshio, ed. Recent Advances in Management of Digestive Cancers. Tokyo: Springer Japan, 1993. http://dx.doi.org/10.1007/978-4-431-68252-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

A, Ajani Jaffer, and Hoff Paulo M, eds. Atlas of gastrointestinal cancers. Philadelphia: Current Medicine, 2006.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

K, Rustgi Anil, ed. Gastrointestinal cancers: Biology, diagnosis, and therapy. Philadelphia: Lippincott-Raven, 1995.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

1935-, Takahashi T., ed. Recent advances in management of digestive cancers: Proceedings of UICC Kyoto International Symposium on Recent Advances in Management of Digestive Cancers, March 31-April 2, 1993. Tokyo: Springer-Verlag, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

K, Rustgi Anil, and Crawford James M. 1954-, eds. Gastrointestinal cancers: A companion to Sleisenger and Fordtran's gastrointestinal and liver disease. Edinburgh: Saunders, 2003.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

National Cancer Institute (U.S.), ed. Biology of and novel therapeutic approaches for epithelial cancers of the aerodigestive tract: Proceedings of a conference held at Steamboat Springs, Colorado, April 1-7, 1991. Bethesda, MD: National Cancer Institute, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Keystone Symposia on Molecular and Cellular Biology (1991 Steamboat Springs, Colo.). Biology of and novel therapeutic approaches for epithelial cancers of the aerodigestive tract: Proceedings of a conference held at Steamboat Springs, Colorado, April 1-7, 1991. Bethesda, MD: National Cancer Institute, 1992.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Rougier, Philippe, Emmanuel Mitry, Sophie Dominguez-Tinajero, and Julien Taïeb. Les cancers digestifs. Paris: Springer Paris, 2006. http://dx.doi.org/10.1007/2-287-30874-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

J, Belcastro V., and Dobelbower Ralph R, eds. Gastrointestinal cancer: Radiation therapy. Berlin: Springer-Verlag, 1990.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Digestive cancers"

1

Pujol, B., B. Napoléon, and L. Palazzo. "Cancers du pancréas." In Écho-endoscopie digestive, 237–44. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-287-99164-6_28.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Bories, E. "Cancers de l’anus." In Écho-endoscopie digestive, 333–38. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-287-99164-6_43.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

des Guetz, G., and P. Wind. "Urgences en cancérologie digestive." In Les cancers digestifs, 337–43. Paris: Springer Paris, 2006. http://dx.doi.org/10.1007/2-287-30874-1_18.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Panzini, B., and P. Poitras. "Genes and Digestive Cancers." In The Digestive System: From Basic Sciences to Clinical Practice, 397–401. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-030-98381-9_25.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Bécouarn, Y. "Osseous metastases of digestive cancers." In Vertebral metastases, 134–37. Paris: Springer Paris, 2002. http://dx.doi.org/10.1007/978-2-8178-0757-7_16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Heath, Amy. "Cancers of the Digestive System." In Radiation Therapy Study Guide, 127–35. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3258-0_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Seely, S. "Cancers of the Digestive Tract." In Diet-Related Diseases, 168–89. London: Routledge, 2022. http://dx.doi.org/10.1201/9781003284369-5.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Sepulveda, Jorge L. "Serological Markers of Digestive Tract Cancers." In Molecular Pathology Library, 249–70. Boston, MA: Springer US, 2012. http://dx.doi.org/10.1007/978-1-4614-6015-2_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Stephens, Frederick O., and Karl Reinhard Aigner. "Cancers of the Digestive System (Alimentary Tract)." In Basics of Oncology, 171–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 2009. http://dx.doi.org/10.1007/978-3-540-92925-3_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Stephens, Frederick O., and Karl Reinhard Aigner. "Cancers of the Digestive System (Alimentary Tract)." In Basics of Oncology, 211–34. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23368-0_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Digestive cancers"

1

Zeng, Tao, Xiangtian Yu, and Chengming Zhang. "IDDF2019-ABS-0120 Pan-cancer study of progressive protein signatures for digestive cancers." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.29.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Nogueira, Leticia, Amanda Cross, Neal Freedman, Gabriel Lai, Felipe Castro, and Jill Koshiol. "Abstract 4804: Gallstones, cholecystectomy, and risk of digestive system cancers." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4804.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Wheeler, David A., Marie-Claude Gingras, Ronald Cotton, Jacques Guiteau, Sally Hodges, Min Wang, Yuan-Qing Wu, et al. "Abstract 2218: Whole exome DNA sequencing in human cancers of the digestive system." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2218.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Moullec, A., E. Bories, JP Ratone, F. Caillol, C. Pesenti, C. Cador, F. Poizat, and M. Giovannini. "L'ampullectomie endoscopique peut elle être curative pour les cancers ampullaires? Résultats d'une étude rétrospective monocentrique." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680960.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Morabit, S., H. Seddik, F. Bouhamou, S. Mrabti, I. El Koti, S. Sentissi, and A. Benkirane. "Drainage biliaire endoscopique dans les cancers bilio-pancréatiques: résultats et facteurs associés à propos de 105 cas." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680885.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hoibian, S., F. Caillol, A. Autret, JP Ratone, C. Pesenti, E. Bories, J. guiramand, P. Ries, S. Dermeche, and M. Giovannini. "Apport de l'echoendoscopie dans la prise en charge chirurgicale des cancers de l'estomac et de la jonction oesogastrique." In Journées Francophones d'Hépato-Gastroentérologie et d'Oncologie Digestive (JFHOD). Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1680881.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Koh, Benjamin, Darren Jun-Hao Tan, Cheng-Han Ng, Wen-Hui Lim, Rebecca Wenling Zeng, Clarissa Elysia Fu, Jieling Xiao, et al. "IDDF2023-ABS-0012 Gastrointestinal cancers are the leading cause of young onset cancer in the United States." In Abstracts of the International Digestive Disease Forum (IDDF), Hong Kong, 10–11 June 2023. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2023. http://dx.doi.org/10.1136/gutjnl-2023-iddf.159.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Mutalib, Nurul-Syakima Ab, Ryia Illani Mohd Yunos, Najwa Farhah Mohd Yusof, Muhiddin Ishak, Sazuita Saidin, Isa Mohamed Rose, Luqman Mazlan, Ismail Sagap, and Rahman Jamal. "IDDF2019-ABS-0312 The landscape of recurrent noncoding mutations in colorectal cancers." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.70.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

LiYa, Huang. "IDDF2019-ABS-0057 The clinical follow-up analysis of 127 pancreatic cancers patients." In International Digestive Disease Forum (IDDF) 2019, Hong Kong, 8–9 June 2019. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2019. http://dx.doi.org/10.1136/gutjnl-2019-iddfabstracts.131.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Yu, Haiying, Baljendra Kapoor, and Gordan McLennan. "Advanced Imaging and Navigation Tools in Minimally Invasive Management of Liver Cancers." In Abstracts of 5th Annual Meeting of the American Society of Digestive Disease Interventions. Thieme Medical Publishers, 2019. http://dx.doi.org/10.1055/s-0039-1689017.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Digestive cancers"

1

Huang, Lumi, Lihui Chen, and Yiming Wang. Nestin and the survival of patients with digestive tract cancers. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2022. http://dx.doi.org/10.37766/inplasy2022.8.0087.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Yu, Dongli, Jingting Liu, Chunyan Meng, Baoqing Liu, and Jianhua Liao. Pan-immune-inflammation value as a Novel Prognostic Biomarker for Digestive System Cancers: A Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2024. http://dx.doi.org/10.37766/inplasy2024.9.0087.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Xia, Zhiyu, Yufei Wang, Fu Liu, Hongxin Shu, Bin Zhou, Miaomiao Zuo, Xianwen Liu, and Xiaomei Huang. Different effects of miRNA-499 polymorphism on digestive tract cancers susceptibility in eastern and western China：a meta-analysis and trial sequential analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0006.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

F. Al-Sanea, Hamad. Evaluation of Recent Surgical Updates Regarding Diagnosis and Management of Diverticulitis. Science Repository, April 2024. http://dx.doi.org/10.31487/j.jsr.2024.01.01.

Повний текст джерела
Анотація:
Diverticulosis occurs when small, bulging pouches (diverticula) develop in your digestive tract. When one or more of these pouches become inflamed or infected, the condition is called diverticulitis. Diverticula are small, bulging pouches that can form in the lining of your digestive system, although it was rare before the 20th century, diverticular disease is now one of the most common health problems in the western world. It’s a group of conditions that can affect your digestive tract. The most serious type of diverticular disease is diverticulitis. It can cause uncomfortable symptoms and, in some cases, serious complications. If left untreated, these complications can cause long-term health problems. Read on to learn more about diverticulitis, including its causes, symptoms, treatment options, and how your diet might affect your risk of developing it. Objective: In this paper, our main focus was on diverticulitis and surgical intervention, and only relevant studies were discussed. Methodology: PubMed database was used for articles selection, and papers on diverticulitis were obtained and reviewed. Conclusion: Colonoscopy is best avoided in acute and uncomplicated diverticulitis. Classically, it is a surgical disease but uncomplicated cases can often be managed conservatively. Follow up of treated diverticulitis occurs after four weeks via colonoscopy, in selected cases assessing the risk of developing colonic cancer. Novel therapies are under-studied and are probable replacements for surgical intervention.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Digestive cancers" для конкретних типів джерел:
Статті в журналах Дисертації Книги
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії